Q1 Earnings Estimate for QuidelOrtho Issued By William Blair

QuidelOrtho Co. (NASDAQ:QDEL - Free Report) - Equities research analysts at William Blair lowered their Q1 2025 earnings per share (EPS) estimates for shares of QuidelOrtho in a research note issued to investors on Wednesday, April 30th. William Blair analyst A. Brackmann now anticipates that the company will post earnings per share of $0.54 for the quarter, down from their prior forecast of $0.63. The consensus estimate for QuidelOrtho's current full-year earnings is $2.30 per share. William Blair also issued estimates for QuidelOrtho's FY2025 earnings at $2.18 EPS, Q1 2026 earnings at $0.62 EPS, Q2 2026 earnings at $0.38 EPS and FY2026 earnings at $2.89 EPS.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) last issued its earnings results on Wednesday, February 12th. The company reported $0.63 EPS for the quarter, missing analysts' consensus estimates of $1.07 by ($0.44). QuidelOrtho had a positive return on equity of 3.78% and a negative net margin of 72.84%.

Other research analysts also recently issued research reports about the company. JPMorgan Chase & Co. dropped their price target on QuidelOrtho from $38.00 to $25.00 and set an "underweight" rating on the stock in a research note on Monday, April 21st. UBS Group lifted their target price on shares of QuidelOrtho from $43.00 to $45.00 and gave the company a "neutral" rating in a report on Thursday, February 13th. Royal Bank of Canada reduced their price target on shares of QuidelOrtho from $64.00 to $61.00 and set an "outperform" rating for the company in a research report on Thursday, February 13th. Finally, StockNews.com downgraded shares of QuidelOrtho from a "buy" rating to a "hold" rating in a research report on Saturday, February 15th. One analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, QuidelOrtho has a consensus rating of "Hold" and an average target price of $46.83.

QuidelOrtho Stock Performance

QDEL traded down $0.24 on Friday, reaching $25.71. The company had a trading volume of 1,034,107 shares, compared to its average volume of 1,018,094. The company has a quick ratio of 0.69, a current ratio of 1.22 and a debt-to-equity ratio of 0.71. QuidelOrtho has a 1 year low of $23.77 and a 1 year high of $49.45. The stock has a market capitalization of $1.73 billion, a PE ratio of -0.85 and a beta of 0.13. The stock has a 50-day moving average price of $31.80 and a 200-day moving average price of $38.28.

Institutional Trading of QuidelOrtho

A number of institutional investors have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. grew its holdings in QuidelOrtho by 19.6% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 11,238,826 shares of the company's stock valued at $500,690,000 after purchasing an additional 1,840,667 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of QuidelOrtho by 12.6% in the 4th quarter. Vanguard Group Inc. now owns 6,817,412 shares of the company's stock valued at $303,716,000 after purchasing an additional 764,900 shares in the last quarter. Invesco Ltd. increased its holdings in QuidelOrtho by 71.7% in the 4th quarter. Invesco Ltd. now owns 3,447,446 shares of the company's stock valued at $153,584,000 after purchasing an additional 1,439,293 shares in the last quarter. ArrowMark Colorado Holdings LLC boosted its holdings in QuidelOrtho by 5.4% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 1,977,697 shares of the company's stock worth $88,106,000 after acquiring an additional 100,522 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in QuidelOrtho by 14.0% during the 4th quarter. JPMorgan Chase & Co. now owns 1,406,654 shares of the company's stock worth $62,666,000 after buying an additional 173,174 shares during the period. 99.00% of the stock is currently owned by hedge funds and other institutional investors.

About QuidelOrtho

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.